US Patent

US11622991 — Protocol for treatment of lupus nephritis

Method of Use · Assigned to Aurinia Pharmaceuticals Inc · Expires 2037-12-07 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a protocol for treating a proteinuric kidney disease with voclosporin using a pharmacodynamic dosing regimen.

USPTO Abstract

By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3056`	—

Patent Metadata

Patent number: US11622991
Jurisdiction: US
Classification: Method of Use
Expires: 2037-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Aurinia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.